Leaps by Bayer

Leaps by Bayer, founded in 2015, is Bayer AG's strategic impact investment unit focusing on transformative biotechnologies in health and agriculture. Since its inception, Leaps by Bayer has invested over $1.9 billion in more than 60 ventures, targeting significant challenges through ten key "leaps" designed to address pressing global issues. Key investments include Recursion Pharmaceuticals, which focuses on drug discovery using AI, and BlueRock Therapeutics, a company specializing in cell therapy. These investments align with their strategic goals such as curing genetic diseases, developing sustainable organ and tissue replacements, and reducing the environmental impact of agriculture. Leaps by Bayer's portfolio companies operate autonomously, but benefit from Bayer’s active incubation model, which provides resources and strategic guidance. This approach helps them focus on long-term, high-impact results rather than short-term gains. Leaps by Bayer also collaborates globally with partners in industry, academia, and civil society to drive these innovations forward.